ValuEngine upgraded shares of Outlook Therapeutics (NASDAQ:OTLK) from a hold rating to a buy rating in a report published on Thursday morning, ValuEngine reports.
Several other research analysts have also weighed in on OTLK. HC Wainwright assumed coverage on Outlook Therapeutics in a research report on Thursday, July 18th. They set a buy rating and a $8.00 price target on the stock. Oppenheimer assumed coverage on Outlook Therapeutics in a report on Thursday, May 16th. They set an outperform rating and a $12.00 target price on the stock. CIBC assumed coverage on Outlook Therapeutics in a report on Thursday, May 16th. They set an outperform rating and a $12.00 target price on the stock. Finally, Ascendiant Capital Markets assumed coverage on Outlook Therapeutics in a report on Monday, April 22nd. They set a buy rating and a $4.00 target price on the stock. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $9.00.
Shares of NASDAQ:OTLK traded down $0.03 during trading on Thursday, hitting $2.13. 400 shares of the company were exchanged, compared to its average volume of 1,815,577. The stock has a market capitalization of $55.12 million, a PE ratio of -0.20 and a beta of -0.86. Outlook Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $10.96. The firm has a fifty day simple moving average of $2.20.
Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.08. The company had revenue of $0.64 million for the quarter. On average, equities research analysts predict that Outlook Therapeutics will post -2 EPS for the current fiscal year.
An institutional investor recently bought a new position in Outlook Therapeutics stock. Chicago Capital LLC acquired a new stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 19,450 shares of the company’s stock, valued at approximately $40,000. Chicago Capital LLC owned approximately 0.07% of Outlook Therapeutics at the end of the most recent reporting period. Institutional investors own 0.87% of the company’s stock.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
See Also: When can a hold rating present a buying opportunity?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.